143 related articles for article (PubMed ID: 38038788)
1. Identification of Optimal Parameters for Assessing Lymph Node Status of Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
Huang X; Jiang D; Jian Z; Zeng Z; Zhang S; Fan H; Sun T; Tang H; Hou Y; Tan L
Ann Surg Oncol; 2024 Feb; 31(2):883-891. PubMed ID: 38038788
[TBL] [Abstract][Full Text] [Related]
2. External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer.
Brinkmann S; Noordman BJ; Hölscher AH; Biermann K; van Klaveren D; Bollschweiler E; Pütz K; van Lanschot JJB; Drebber U
Ann Surg Oncol; 2020 Apr; 27(4):1250-1258. PubMed ID: 31691114
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Pretreatment Pathological Tumor Extent in Patients Treated With Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal or Junctional Cancer.
Shapiro J; Biermann K; van Klaveren D; Offerhaus GJ; Ten Kate FJ; Meijer SL; van Berge Henegouwen MI; Steyerberg EW; Wijnhoven BP; Lanschot JJ
Ann Surg; 2017 Feb; 265(2):356-362. PubMed ID: 28059964
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of positive lymph node regression grade to neoadjuvant chemoradiation for esophageal squamous cell carcinoma.
Yehan Z; Ying L; Peng G; Zongyao H; Chengmin Z; Hong Y; Sheng Q; Jie Z; Yi W; Xuefeng L; Wenwu H; Qifeng W; Yang L
J Surg Oncol; 2024 Mar; 129(4):708-717. PubMed ID: 38124398
[TBL] [Abstract][Full Text] [Related]
5. Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
Yun JK; Kim Y; Lee GD; Choi S; Kim YH; Kim DK; Park SI; Kim HR
Cancer Med; 2022 Oct; 11(19):3623-3632. PubMed ID: 35434935
[TBL] [Abstract][Full Text] [Related]
6. A Novel Tumor Staging System Incorporating Tumor Regression Grade (TRG) With Lymph Node Status (ypN-Category) Results in Better Prognostication Than ypTNM Stage Groups After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.
Wong IYH; Chung JCY; Zhang RQ; Gao X; Lam KO; Kwong DLW; Chao YK; Law SYK
Ann Surg; 2022 Nov; 276(5):784-791. PubMed ID: 35876374
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
[TBL] [Abstract][Full Text] [Related]
8. Increased resected lymph node stations improved survival of esophageal squamous cell carcinoma.
Lu RD; Wei ZD; Liu YX; Tian D; Zhang HL; Shang QX; Hu WP; Yang L; Yang YS; Chen LQ
BMC Cancer; 2024 Feb; 24(1):177. PubMed ID: 38317075
[TBL] [Abstract][Full Text] [Related]
9. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
10. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
Tu CC; Hsu PK; Chien LI; Liu WC; Huang CS; Hsieh CC; Hsu HS; Wu YC
BMC Cancer; 2017 Jan; 17(1):62. PubMed ID: 28103913
[TBL] [Abstract][Full Text] [Related]
11. Nodal Downstaging of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy: Survival Analysis if ypN0 Is Achieved.
Tang H; Tan L; Wang H; Shen Y; Yin J
J Gastrointest Surg; 2020 Jul; 24(7):1469-1476. PubMed ID: 31346888
[TBL] [Abstract][Full Text] [Related]
12. Lymph node ratio-based staging system for esophageal squamous cell carcinoma.
Chen SB; Weng HR; Wang G; Zou XF; Liu DT; Chen YP; Zhang H
World J Gastroenterol; 2015 Jun; 21(24):7514-21. PubMed ID: 26139998
[TBL] [Abstract][Full Text] [Related]
13. Lymph Node Ratio Improves Prediction of Overall Survival in Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy: A National Cancer Database Analysis.
Zhang Y; Cao Y; Zhang J; Huang M; Roy P; Huang B; Yang H; Rong Y; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Lin J; Zhang J; Fu J; He J; Li H
Ann Surg; 2023 Jun; 277(6):e1239-e1246. PubMed ID: 35797545
[TBL] [Abstract][Full Text] [Related]
14. Lymph node volume predicts survival in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery.
Pao TH; Chen YY; Chang WL; Wu SY; Lai WW; Tseng YL; Chung TJ; Lin FC
PLoS One; 2024; 19(3):e0300173. PubMed ID: 38547184
[TBL] [Abstract][Full Text] [Related]
15. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of patients with esophageal squamous cell carcinoma after esophagectomy using the log odds of positive lymph nodes.
Wu SG; Sun JY; Yang LC; Zhou J; Li FY; Li Q; Lin HX; Lin Q; He ZY
Oncotarget; 2015 Nov; 6(34):36911-22. PubMed ID: 26426993
[TBL] [Abstract][Full Text] [Related]
17. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of
Hamai Y; Hihara J; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Aoki Y; Furukawa T; Okada M
Ann Surg Oncol; 2019 Jun; 26(6):1869-1878. PubMed ID: 30675704
[TBL] [Abstract][Full Text] [Related]
20. SUV
Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
World J Surg Oncol; 2021 Apr; 19(1):105. PubMed ID: 33836789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
